Hydroxyurea in sickle cell disease: What will it take to change practice?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia.Scientific reports · 2020
   Article
2. α:Non-α and Gγ:Aγ globin chain ratios in thalassemia intermedia patients treated with hydroxyurea.Asian Pacific journal of tropical biomedicine · 2014
   Article
3. Replication stress and mechanisms of CNV formation.Current opinion in genetics & development · 2012
   Review
4. Hydroxyurea induces de novo copy number variants in human cells.Proceedings of the National Academy of Sciences of the United States of America · 2011
   Article
5. Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B.Hepatitis monthly · 2011
   Article

Corrections and comments

• Comment on
  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as